Blood products company Haemonetics (NYSE: HAE). will be announcing earnings results this Thursday morning. Here’s what to expect.
Haemonetics beat analysts’ revenue expectations by 6.6% last quarter, reporting revenues of $321.4 million, down 4.4% year on year. It was a very strong quarter for the company, with a solid beat of analysts’ organic revenue estimates and an impressive beat of analysts’ revenue estimates.
Is Haemonetics a buy or sell going into earnings? Read our full analysis here, it’s free for active Edge members.
This quarter, analysts are expecting Haemonetics’s revenue to decline 10% year on year to $310.8 million, a reversal from the 8.6% increase it recorded in the same quarter last year. Adjusted earnings are expected to come in at $1.11 per share.
Analysts covering the company have generally reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. Haemonetics has only missed Wall Street’s revenue estimates once over the last two years, exceeding top-line expectations by 2.2% on average.
Looking at Haemonetics’s peers in the medical devices & supplies - specialty segment, some have already reported their Q3 results, giving us a hint as to what we can expect. Inspire Medical Systems delivered year-on-year revenue growth of 10.5%, beating analysts’ expectations by 1.9%, and Bausch + Lomb reported revenues up 7.1%, in line with consensus estimates. Inspire Medical Systems traded up 15.6% following the results while Bausch + Lomb’s stock price was unchanged.
Read our full analysis of Inspire Medical Systems’s results here and Bausch + Lomb’s results here.
Investors in the medical devices & supplies - specialty segment have had steady hands going into earnings, with share prices flat over the last month. Haemonetics is up 1.7% during the same time and is heading into earnings with an average analyst price target of $76.27 (compared to the current share price of $50.38).
P.S. In tech investing, "Gorillas" are the rare companies that dominate their markets—like Microsoft and Apple did decades ago. Today, the next Gorilla is emerging in AI-powered enterprise software. So, in that spirit, we are excited to present our Special Free Report on a profitable, fast-growing enterprise software stock that is already riding the automation wave and looking to catch the generative AI next.
StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here.
